FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1915258965> ?p ?o ?g. }

• W1915258965 endingPage "640" @default.
• W1915258965 startingPage "634" @default.
• W1915258965 abstract "The potency, efficacy, and pharmacokinetic properties of IDN-6556 (3-[2-[(2-tert-butyl-phenylaminooxalyl)-amino]-propionylamino]-4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-pentanoic acid), a first-in-class caspase inhibitor in clinical trials for the treatment of liver diseases, were characterized in vivo in rodent models. In the mouse alpha-Fas model of liver injury, i.p. administration of IDN-6556 resulted in marked reduction of alanine aminotransferase (ALT), apoptosis, and caspase activities at a dose of 3 mg/kg. At this dose, IDN-6556 was also effective when given up to 2 h before alpha-Fas and as late as 4 h after alpha-Fas administration. In both the alpha-Fas and d-galactosamine/lipopolysaccharide (D-Gln/LPS) model, ED(50) values in the sub-milligram per kilogram range were established after a number of routes of administration (i.p., i.v., i.m., or p.o.), ranging from 0.04 to 0.38 mg/kg. Efficacy was also demonstrated in the rat D-Gln/LPS model with 67 and 72% reductions in ALT activities after i.p. and p.o. treatment with IDN-6556 (10 mg/kg), respectively. Pharmacokinetic analysis in the rat demonstrated rapid clearance after i.v., i.p., and s.c. administration with terminal t(1/2) ranging from 46 to 51 min. Low absolute bioavailability after p.o. administration was seen (2.7-4%), but portal drug concentrations after oral administration were 3-fold higher than systemic concentrations with a 3.7-fold increase in the terminal t(1/2), indicating a significant first-pass effect. Liver concentrations remained constant after oral administration for at least a 4-h period, reaching a C(max) of 2558 ng/g liver at 120 min. Last, 51 +/- 20 and 4.9 +/- 3.4% of IDN-6556 was excreted intact in bile after i.v. and p.o. administration, respectively. This evaluation indicates that IDN-6556 has marked efficacy in models of liver disease after oral administration and thus, is an excellent candidate for the treatment of liver diseases characterized by excessive apoptosis." @default.
• W1915258965 created "2016-06-24" @default.
• W1915258965 creator A5010213274 @default.
• W1915258965 creator A5020607094 @default.
• W1915258965 creator A5031517492 @default.
• W1915258965 creator A5049285430 @default.
• W1915258965 creator A5070674019 @default.
• W1915258965 creator A5090325950 @default.
• W1915258965 date "2004-01-23" @default.
• W1915258965 modified "2023-10-16" @default.
• W1915258965 title "Characterization of IDN-6556 (3-{2-(2-<i>tert</i>-Butyl-phenylaminooxalyl)-amino]-propionylamino}-4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-pentanoic Acid): a Liver-Targeted Caspase Inhibitor" @default.
• W1915258965 cites W1882996705 @default.
• W1915258965 cites W1942214720 @default.
• W1915258965 cites W1964893077 @default.
• W1915258965 cites W1967912613 @default.
• W1915258965 cites W1979998867 @default.
• W1915258965 cites W2003478049 @default.
• W1915258965 cites W2005183316 @default.
• W1915258965 cites W2028135427 @default.
• W1915258965 cites W2032555321 @default.
• W1915258965 cites W2040411965 @default.
• W1915258965 cites W2051515172 @default.
• W1915258965 cites W2057210920 @default.
• W1915258965 cites W2067534266 @default.
• W1915258965 cites W2072454412 @default.
• W1915258965 cites W2076231007 @default.
• W1915258965 cites W2124132939 @default.
• W1915258965 cites W2132024844 @default.
• W1915258965 cites W2153225914 @default.
• W1915258965 cites W2160141634 @default.
• W1915258965 doi "https://doi.org/10.1124/jpet.103.062034" @default.
• W1915258965 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14742742" @default.
• W1915258965 hasPublicationYear "2004" @default.
• W1915258965 type Work @default.
• W1915258965 sameAs 1915258965 @default.
• W1915258965 citedByCount "87" @default.
• W1915258965 countsByYear W19152589652012 @default.
• W1915258965 countsByYear W19152589652013 @default.
• W1915258965 countsByYear W19152589652014 @default.
• W1915258965 countsByYear W19152589652015 @default.
• W1915258965 countsByYear W19152589652016 @default.
• W1915258965 countsByYear W19152589652017 @default.
• W1915258965 countsByYear W19152589652018 @default.
• W1915258965 countsByYear W19152589652019 @default.
• W1915258965 countsByYear W19152589652020 @default.
• W1915258965 countsByYear W19152589652021 @default.
• W1915258965 countsByYear W19152589652022 @default.
• W1915258965 countsByYear W19152589652023 @default.
• W1915258965 crossrefType "journal-article" @default.
• W1915258965 hasAuthorship W1915258965A5010213274 @default.
• W1915258965 hasAuthorship W1915258965A5020607094 @default.
• W1915258965 hasAuthorship W1915258965A5031517492 @default.
• W1915258965 hasAuthorship W1915258965A5049285430 @default.
• W1915258965 hasAuthorship W1915258965A5070674019 @default.
• W1915258965 hasAuthorship W1915258965A5090325950 @default.
• W1915258965 hasConcept C112705442 @default.
• W1915258965 hasConcept C150903083 @default.
• W1915258965 hasConcept C181389837 @default.
• W1915258965 hasConcept C185592680 @default.
• W1915258965 hasConcept C202751555 @default.
• W1915258965 hasConcept C207001950 @default.
• W1915258965 hasConcept C2777056448 @default.
• W1915258965 hasConcept C55493867 @default.
• W1915258965 hasConcept C57992300 @default.
• W1915258965 hasConcept C71924100 @default.
• W1915258965 hasConcept C86803240 @default.
• W1915258965 hasConcept C98274493 @default.
• W1915258965 hasConceptScore W1915258965C112705442 @default.
• W1915258965 hasConceptScore W1915258965C150903083 @default.
• W1915258965 hasConceptScore W1915258965C181389837 @default.
• W1915258965 hasConceptScore W1915258965C185592680 @default.
• W1915258965 hasConceptScore W1915258965C202751555 @default.
• W1915258965 hasConceptScore W1915258965C207001950 @default.
• W1915258965 hasConceptScore W1915258965C2777056448 @default.
• W1915258965 hasConceptScore W1915258965C55493867 @default.
• W1915258965 hasConceptScore W1915258965C57992300 @default.
• W1915258965 hasConceptScore W1915258965C71924100 @default.
• W1915258965 hasConceptScore W1915258965C86803240 @default.
• W1915258965 hasConceptScore W1915258965C98274493 @default.
• W1915258965 hasIssue "2" @default.
• W1915258965 hasLocation W19152589651 @default.
• W1915258965 hasLocation W19152589652 @default.
• W1915258965 hasOpenAccess W1915258965 @default.
• W1915258965 hasPrimaryLocation W19152589651 @default.
• W1915258965 hasRelatedWork W1555144605 @default.
• W1915258965 hasRelatedWork W1970245702 @default.
• W1915258965 hasRelatedWork W2001333918 @default.
• W1915258965 hasRelatedWork W2028112905 @default.
• W1915258965 hasRelatedWork W2086460393 @default.
• W1915258965 hasRelatedWork W2314489661 @default.
• W1915258965 hasRelatedWork W2317627837 @default.
• W1915258965 hasRelatedWork W2379311614 @default.
• W1915258965 hasRelatedWork W2414263157 @default.
• W1915258965 hasRelatedWork W2753834235 @default.
• W1915258965 hasVolume "309" @default.
• W1915258965 isParatext "false" @default.
• W1915258965 isRetracted "false" @default.
• W1915258965 magId "1915258965" @default.

• next